The influence of OKT3 therapy on hepatocellular carcinoma recurrence following liver transplantation

Clinical Transplantation

Volumn 24, Issue 4, 2010, Pages

  Zimmerman, Michael A ^a   Kelly, Mara A ^a   Campsen, Jeffrey ^a   Mandell, M Susan ^b   Wachs, Michael ^a   Bak, Tom ^a   Skibba, Afshin ^a   Lancaster, Brian ^a   Kam, Igal ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Department of Anesthesia ^*  (United States)

Author keywords

Hepatocellular carcinoma; Recurrence; Sirolimus

Indexed keywords

METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MUROMONAB-CD3; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77955725860     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01179.x     Document Type: Article

References (12)

1. Regalia E, Fassati LR, Valente U. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg 1998, 5:29.
2. Margarit C, Charco R, Hidalgo E, Allende H, Castells L, Bilbao I. Liver transplantation for malignant diseases: selection and pattern of recurrence. World J Surg 2002, 26:257.
3. Pawlik TM, Delman KA, Vauthey JN. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005, 11:1086.
4. Zimmerman MA, Trotter JF, Wachs M. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl Int 2007, 20:747.
5. Vivarelli M, Cucchetti A, Piscaglia F. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005, 11:497.
6. Decaens T, Roudot-Thoraval F, Bresson-Hadni S. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol 2006, 12:7319.
7. Parfitt JR, Marotta P, Alghamdi M. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl 2007, 13:543.
8. Greene FL, Page DL, Felming ID. AJCC Cancer Staging Manual 2002, 6th edn, New York, Springer
9. Edmondson H, Steiner P. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954, 1:462.
10. Zimmerman MA, Ghobrial RM, Tong MJ. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008, 143:182. discussion 8
11. Zimmerman MA, Trotter JF, Wachs M. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008, 14:633.
12. Rosen HR, Shackleton CR, Higa L. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997, 92:1453.